알리코제약

260660KOSDAQ의료용품 및 기타 의약 관련제품 제조업

43.0 / 100

Reference Date: 2026-04-13

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Alico Pharmaceutical, established in 1992, operates in pharmaceutical manufacturing and sales, CMO, overseas exports, medical device production, and the development and sale of health functional foods and cosmetics. The company expanded its central research institute in 2020 to enhance new growth initiatives. It has maintained profitability, achieving a 13.69% CAGR in revenue from 2012 to 2025. Alico aims to capitalize on increasing pharmaceutical demand driven by an aging population and is expanding into medical devices, cosmetics, and other sectors to strengthen revenue and growth.

Number of Employees

228people

Average Salary

53.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

0.66Industry Average 1.627.0Point

Half of industry avg (excellent)

ROE

-0.77Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

25.16Industry Average 8.880.0Point

2.8x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼74.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 3,385Won52-week high 5,05052-week low 3,145

1-month return3.0Point

1m -1.17% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19